Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
CONTEXT: The gut hormone, oxyntomodulin, is a proglucagon product with body weight-lowering potential. It binds to both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor; however, the mechanism behind the body weight-lowering effect remains elusive. OBJECTIVE: We wanted to delineate the contributions of separate and combined GLP-1 receptor and glucagon receptor activation to the body weight-reducing mechanisms of oxyntomodulin. DESIGN: This was a double-blinded, randomized, crossover study. SETTING: The study was conducted at a specialized research unit. PARTICIPANTS: Fifteen young healthy male volunteers (aged 22 [range 18-32] y; body mass index 23 [21-26] kg/m(2); fasting plasma glucose 5.1 [4.4-5.4] mmol/L; and glycated hemoglobin A1c 40 (37-42) mmol/mol). INTERVENTIONS: Five 4-hour liquid meal tests during the infusion of saline, GLP-1 (1 pmol × kg(-1) × min(-1)), glucagon (0.86 pmol × kg(-1) × min(-1)), oxyntomodulin (3 pmol × kg(-1) × min(-1)), or glucagon+GLP-1 (same doses). MAIN OUTCOME MEASURES: We evaluated resting energy expenditure (measured as oxygen uptake, gastric emptying (GE), composite appetite scores (CAS), and food intake. RESULTS: Oxyntomodulin, GLP-1, and GLP-1+glucagon slowed GE and reduced CAS, whereas glucagon did not affect GE and CAS. All infusions caused a similar decrease in food intake compared with saline (total intake (g [95% confidence interval]), saline 811 [729, 892], GLP-1 669 [586, 750], glucagon 686 [604, 768], oxyntomodulin 689 [608, 771], and glucagon+GLP-1 688 [606, 769]). Oxygen uptake did not change significantly from baseline in response to any peptide infusion compared with saline. CONCLUSIONS: Oxyntomodulin, GLP-1, and glucagon decreased food intake but with no additional effect of combining GLP-1 and glucagon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 4×
“2] AUC, min mmol/L 273 [213, 308] 205 [160, 233] 250 [195, 283] 221 [171, 248] 218 [167 242] Saline [ 37, 9]% [ 23, 10]% [ 33, 3]% [ 34, 6]% GLP-1 [1, 43]% [ 12, 28]% [ 14, 25]% Glucagon [ 27, 5]% [ 29, 3]% Oxyntomodulin [ 19, 17]% NEFAs Baseline, mmol/L 0.”
InfluentialSelf-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 2×
“2] AUC, min mmol/L 273 [213, 308] 205 [160, 233] 250 [195, 283] 221 [171, 248] 218 [167 242] Saline [ 37, 9]% [ 23, 10]% [ 33, 3]% [ 34, 6]% GLP-1 [1, 43]% [ 12, 28]% [ 14, 25]% Glucagon [ 27, 5]% [ 29, 3]% Oxyntomodulin [ 19, 17]% NEFAs Baseline, mmol/L 0.”
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Linear mixed models for longitudinal data
(2000) · Springer Series in Statistics · doi:10.1007/b98969 · Cited by 818
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“Glucagon [ 45, 19]% [ 47, 21]% Oxyntomodulin [ 20, 18]% AUC, min mmol/L 178 [160, 195] 160 [142, 177] 189 [171, 207] 163 [145, 180] 172 [155, 180] Saline [ 36, 1] [ 7, 30] [ 33, 4] [ 24, 13] GLP-1 [11, 48] [ 15, 22] [ 6, 31] Glucagon [ 44, 8] [ 35, 2] Oxyntomodulin [ 9, 27] ISR Peak, pmol/kg min 12 [11, 14] 6 [5, 7] 1…”
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 2×
“Glucagon [ 45, 19]% [ 47, 21]% Oxyntomodulin [ 20, 18]% AUC, min mmol/L 178 [160, 195] 160 [142, 177] 189 [171, 207] 163 [145, 180] 172 [155, 180] Saline [ 36, 1] [ 7, 30] [ 33, 4] [ 24, 13] GLP-1 [11, 48] [ 15, 22] [ 6, 31] Glucagon [ 44, 8] [ 35, 2] Oxyntomodulin [ 9, 27] ISR Peak, pmol/kg min 12 [11, 14] 6 [5, 7] 1…”
Self-citationBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Research works printed but not linked: 29
- Schjoldager, 1988, Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man, Eur J Clin Invest, 18, 499, 10.1111/j.1365-2362.1988.tb01046.x · DOI · Paper page
- Dakin, 2001, Oxyntomodulin inhibits food intake in the rat, Endocrinology, 142, 4244, 10.1210/endo.142.10.8430 · DOI · Paper page
- Gros, 1993, Glucagon-like peptide-1-(7–36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line, Endocrinology, 133, 631, 10.1210/endo.133.2.8102095 · DOI · Paper page
- Baldissera, 1988, Oxyntomodulin (glicentin-(33–69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs, Regul Pept, 21, 151, 10.1016/0167-0115(88)90099-7 · DOI
- Holst, 1997, Enteroglucagon, Annu Rev Physiol, 59, 257, 10.1146/annurev.physiol.59.1.257 · DOI · Paper page
- Holst, 1983, Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin—current status, Gastroenterology, 84, 1602, 10.1016/0016-5085(83)90388-8 · DOI
- Holst, 1982, Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33–69) of glicentin, Biochem J, 207, 381, 10.1042/bj2070381 · DOI · Paper page
- Druce, 2009, Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs, Endocrinology, 150, 1712, 10.1210/en.2008-0828 · DOI · Paper page
- Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 273, E981
- Penick, 1961, Depression of food intake induced in healthy subjects by glucagon, N Engl J Med, 264, 893, 10.1056/NEJM196105042641801 · DOI · Paper page
- Schulman, 1957, Effect of glucagon on food intake and body weight in man, J Appl Physiol, 11, 419, 10.1152/jappl.1957.11.3.419 · DOI · Paper page
- Geary, 1992, Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men, Am J Physiol, 262, R975
- Pocai, 2009, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58, 2258, 10.2337/db09-0278 · DOI · Paper page
- Kosinski, 2012, The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin, Obes (Silver Spring Md), 20, 1566, 10.1038/oby.2012.67 · DOI · Paper page
- Gregersen, 2008, Reproducibility and power of ad libitum energy intake assessed by repeated single meals, Am J Clin Nutr, 87, 1277, 10.1093/ajcn/87.5.1277 · DOI
- Orskov, 1994, Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans, Diabetes, 43, 535, 10.2337/diab.43.4.535 · DOI · Paper page
- Albrechtsen, 2014, Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?, Diabetologia, 57, 1919, 10.1007/s00125-014-3283-z · DOI · Paper page
- Sloth, 2009, The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period, Br J Nutr, 101, 1846, 10.1017/S0007114508137710 · DOI · Paper page
- Van Cauter, 1992, Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance, Diabetes, 41, 368, 10.2337/diabetes.41.3.368 · DOI
- Kjems, 2000, Validation of methods for measurement of insulin secretion in humans in vivo, Diabetes, 49, 580, 10.2337/diabetes.49.4.580 · DOI · Paper page
- Kjems, 2001, Quantification of β-cell function during IVGTT in type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods, Diabetologia, 44, 1339, 10.1007/s001250100639 · DOI
- D'Alessio, 1988, Thermic effect of food in lean and obese men, J Clin Invest, 81, 1781, 10.1172/JCI113520 · DOI · Paper page
- Shalev, 1997, Effects of glucagon-like peptide 1 (7–36 amide) on whole-body protein metabolism in healthy man, Eur J Clin Invest, 27, 10, 10.1046/j.1365-2362.1997.540613.x · DOI · Paper page
- Tan, 2013, Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia, Diabetes, 62, 1131, 10.2337/db12-0797 · DOI · Paper page
- Schmidt, 2014, Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men, Am J Physiol Endocrinol Metab, 306, E1248, 10.1152/ajpendo.00569.2013 · DOI · Paper page
- Harder, 2004, The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes, Diabetes Care, 27, 1915, 10.2337/diacare.27.8.1915 · DOI · Paper page
- Taylor, 1975, Glucagon and the colon, Gut, 16, 973, 10.1136/gut.16.12.973 · DOI
- Dotevall, 1963, The effect of glucagon on intestinal motility in man, Gastroenterology, 45, 364, 10.1016/S0016-5085(19)34888-7 · DOI
- Cohen, 2003, Oxyntomodulin suppresses appetite and reduces food intake in humans, J Clin Endocrinol Metab, 88, 4696, 10.1210/jc.2003-030421 · DOI · Paper page
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationSignaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
Glucagon Regulation of Energy Expenditure
Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215407 · Cited by 147
Metadata
- Authors
- Bagger, J. I., Holst, J. J., Hartmann, B., Andersen, B., Knop, F. K., & Vilsbøll, T.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-12-01
- Volume
- 100
- Issue
- 12
- Pages
- 4541-4552
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2150622862
- Cited by
- 88
- References
- 12
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. https://app.cochat.ai/papers/10.1210/jc.2015-2335
- The paper
- Bagger, J. I., Holst, J. J., Hartmann, B., Andersen, B., Knop, F. K., & Vilsbøll, T. (2015). Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2015-2335
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.